• 20% improvement in the number of tender/painful joints & swollen joints, 20% improvement in at least 3 of the following: patient's pain, patient's or physician's global impression of arthritis, functional disability, and c-reactive protein.
  

• Change in the individual components of ACR20 as listed above at each scheduled visit. Subjects discontinuing due to lack of efficacy, use of rescue medication, adverse events, safety measures (labs, ECG, vital signs) and health-related quality of life.
  

Inclusion criteria:

• Rheumatoid arthritis (RA) for at least 12 months.
• Required a non-steroidal anti-inflammatory drug (NSAID) or COX-2 inhibitor for RA for at least 5 out of 7 days of each week for the 4 weeks prior to screening.

Exclusion criteria:

• Any history of cardiovascular disease (e.g., heart attack, stroke, congestive heart failure, uncontrolled high blood pressure), documented peripheral arterial insufficiency and symptomatic, clinically significant claudication, or who have a history of peripheral arterial embolism.
• Have an active stomach ulcer or history of any stomach tear or bleeding.